Status:
COMPLETED
Study Comparing a Pantoprazole Formulation to the Currently Marketed Tablet for GERD and Erosive Esophagitis
Lead Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer
Conditions:
Gastroesophageal Reflux
Esophagitis
Eligibility:
All Genders
18-65 years
Phase:
PHASE3
Brief Summary
The purpose of this study is to demonstrate pharmacodynamic comparability between the pantoprazole spheroid formulation and the marketed tablet formulation.
Eligibility Criteria
Inclusion
- GERD and a history of Erosive Esophagitis documented by endoscopy
- H. pylori negative
Exclusion
- Gastrointestinal conditions such as esophageal stricture, esophageal varices, previous vagotomy
- Achlorhydria
Key Trial Info
Start Date :
June 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2005
Estimated Enrollment :
97 Patients enrolled
Trial Details
Trial ID
NCT00195208
Start Date
June 1 2005
End Date
November 1 2005
Last Update
February 8 2013
Active Locations (9)
Enter a location and click search to find clinical trials sorted by distance.
1
Anaheim, California, United States, 92801
2
Los Angeles, California, United States, 90073
3
Orange, California, United States, 92869
4
San Diego, California, United States, 92103